Private credit has emerged as an attractive asset class for investors seeking enhanced returns, but recent data reveals a critical challenge: manager selection risk.
Notably, the 54 constituents in the VettaFi Private Credit Index showed dramatic performance dispersion in 2025. Returns ranged from positive 20% to negative 30% – a staggering 50-percentage-point spread.
This wide dispersion creates a significant dilemma for investors. “If you were invested in the manager who was up 20%, you’re probably quite pleased with your exposure. On the other hand, if you were invested in the manager who had a 30% negative return, you’re probably not so happy,” Christopher Getter, portfolio manager at Simplify Asset Management, said during a recent webcast.
Traditionally, private credit investing requires a two-step process. First, making an asset allocation decision to invest in private credit. Second, selecting which manager to invest with. This manager selection decision carries substantial risk, as the 2025 data clearly demonstrates.
For advisors, the stakes are particularly high. The consequences of poor manager selection can significantly impact client relationships and portfolio performance.
The Simplify Private Credit Strategy ETF (PCR) addresses this challenge by taking a different approach. Rather than requiring investors to navigate the manager selection minefield, PCR “invests in the entire index, so you will get a much more diversified exposure over the very large breadth of issuers that are active in the private credit space,” Getter said.
This approach consolidates the traditional two-step process into a single decision. “If you just want that to be one decision, which is the asset allocation decision into private credit, PCR is a very expedient way to get that,” Getter explained. By providing broad index exposure, PCR mitigates manager selection risk while maintaining access to the private credit asset class.
For more news, information, and strategy, visit ETF Trends.
vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for PCR, for which it receives an index licensing fee. However, PCR is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of PCR.
One person has died following a two-vehicle collision in Brampton on Friday afternoon. The crash…
VettaFi’s Head of Research Todd Rosenbluth discussed the Victoryshares Free Cash Flow ETF (VFLO) on this…
NewsFeedAnalyst Alexandru Hudisteanu warns that Iran’s overuse of Strait of Hormuz as leverage could transform…
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure Venus Protocol…
Descrease article font size Increase article font size The vice-president of operations for Saskatchewan Public…
“Try adding some tech growth to your portfolio.” That was a suggestion I received last…